Davids Joseph News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Avisa Diagnostics Announces Non-Brokered Private Placement of Common Shares NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Avisa Diagnostics Inc. a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, today announced that it intends to conduct a non-brokered private placement of 1,390,000 common shares of the Company to raise … NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Avisa Diagno...

Avisa Diagnostics Retains Venture Liquidity Providers Inc. for Market-Making Services Avisa Diagnostics Inc. a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 long haulers and for ventilator-associated pneumonia, is pleased to announce that the Company has, subject to regulatory approval, retained Venture Liquidity Providers Inc. to initiate market-making services to provide … Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an...

Share: NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. SANTA FE, N. M., May 04, 2021 (GLOBE NEWSWIRE) -- Avisa Diagnostics Inc. (formerly, FogChain Corp.) (the "Company") is pleased to announce the closing of its previously announced reverse takeover transaction (the "Transaction") with Avisa Pharma Inc. ("Avisa"). In accordance with the merger agreement and plan of reorganization dated February 1, 2021 (the "Merger Agreement"), which superseded and replaced the previously announced Letter of Intent dated January 12, 2021, the Transaction w...

 (CSE: FOG.X) (OTCB: FOGCF) (FRA: MUU3) (the " Company" or " FogChain") is pleased to announce, further to its news release dated January 13, 2021, the Company has entered into a merger agreement and plan of reorganization (the " Definitive Agreement") with Avisa Pharma Inc. (" Avisa") and FogChain USA Inc., a wholly-owned subsidiary of FogChain, dated February 1, 2021, in respect of a statutory merger under the Delaware General Corporation Law pursuant to which the Company has agreed to acquire all of the issued and outstanding shares in the capital of Avisa (the " Avisa Shares"), a private...